Dopesh Raja Mulakala
About Dopesh Raja Mulakala
Data last updated:
Dopesh Raja Mulakala is a Director at Sarvotham Care Limited (since 2010), Managing Director at Vanta Bioscience Limited (since 2016) and Director at Shree Cosmetics Limited (since 2014), and holds 3 more current directorships. The companies operate in FMCG, Pharma and Healthcare. The 6 current companies with reported revenue have a combined latest revenue of ₹45.71 Cr; the largest is Sarvotham Care Limited at ₹31.32 Cr (FY 2024). Earlier, Dopesh Raja Mulakala was a Director at Sarvotham Remedies Limited (2007–2026) and Director at Sarvotham Hexis Private Limited (2025) and 1 more.
Current companies
| Company | Designation | Appointment | Founded | Revenue | Status |
|---|---|---|---|---|---|
 Sarvotham Care Limited U24110TG1995PLC020979 | Director | 15 Sep 2010 | 1995 | ₹31.32 Cr (FY 2024) | Active |
 Vanta Bioscience Limited L74999TG2016PLC109280 | Managing Director | 29 Apr 2016 | 2016 | ₹9.83 Cr (FY 2024) | Active |
 Shree Cosmetics Limited U24246TG2006PLC110691 | Director | 19 Apr 2014 | 2006 | ₹2.79 Cr (FY 2024) | Active |
 Cebis India Limited U73100TG2018PLC127550 | Managing Director | 10 Oct 2018 | 2018 | ₹1.22 Cr (FY 2024) | Active |
| Sarvotham Solutions Limited U73100TG2013PLC088942 | Director | 15 Jul 2013 | 2013 | ₹54.2 Lakh (FY 2025) | Active |
| Vanta Clinical Research Limited U73100TG2018PLC126673 | Director | 12 Sep 2018 | 2018 | ₹1,983 (FY 2021) | Active |
Previous companies
| Company | Designation | Appointment | Founded | Revenue | Status |
|---|---|---|---|---|---|
 Sarvotham Remedies Limited U24239TG2002PLC038573 | Director | 28 Jan 2007 | 2002 | ₹1.69 Cr (FY 2025) | Active |
| Sarvotham Hexis Private Limited U78300TS2025PTC204311 | Director | 22 Sep 2025 | 2025 | Active | |
| Sarvotham Hexis Llp ABZ-5749 | Designated Partner | 22 Dec 2022 | 2022 | Converted And Dissolved |
Explore Director's current and past company associations Uncover their professional journey today!
Board colleagues of Dopesh Raja Mulakala
Directorship timeline
Open interactive timeline →Shareholding and investment profile for Dopesh Raja Mulakala
Company-level share counts, filed values, and quarterly changes require authenticated premium access.
- Company-level holdings
- Filed share counts
- Reported values
- Quarterly changes
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Dopesh Raja Mulakala
Dopesh Raja Mulakala currently holds 6 directorships: Sarvotham Care Limited (Director, since 15 Sep 2010, revenue ₹31.32 Cr (FY 2024)); Vanta Bioscience Limited (Managing Director, since 29 Apr 2016, revenue ₹9.83 Cr (FY 2024)); Shree Cosmetics Limited (Director, since 19 Apr 2014, revenue ₹2.79 Cr (FY 2024)); Cebis India Limited (Managing Director, since 10 Oct 2018, revenue ₹1.22 Cr (FY 2024)); Sarvotham Solutions Limited (Director, since 15 Jul 2013, revenue ₹54.2 Lakh (FY 2025)); and 1 more.
Dopesh Raja Mulakala was first appointed on 28 Jan 2007 as Director at Sarvotham Remedies Limited. The most recent appointment on record is 22 Sep 2025 at Sarvotham Hexis Private Limited.
The 6 current companies of Dopesh Raja Mulakala that report revenue have a combined latest revenue of ₹45.71 Cr: Sarvotham Care Limited ₹31.32 Cr (FY 2024); Vanta Bioscience Limited ₹9.83 Cr (FY 2024); Shree Cosmetics Limited ₹2.79 Cr (FY 2024); Cebis India Limited ₹1.22 Cr (FY 2024); Sarvotham Solutions Limited ₹54.2 Lakh (FY 2025); and 1 more.
Dopesh Raja Mulakala held 3 earlier board appointments: Sarvotham Remedies Limited (Director, 28 Jan 2007 to 03 Jan 2026); Sarvotham Hexis Private Limited (Director, 22 Sep 2025 to 29 Sep 2025); Sarvotham Hexis Llp (Designated Partner, from 22 Dec 2022).
The current boards of Dopesh Raja Mulakala's companies include Basava Raju Dontam Setty (Sarvotham Care Limited), Karishma Chintapatla (Sarvotham Care Limited), Mohan Krishna Mulakala (Sarvotham Care Limited), Ramakrishna Viswanadha (Sarvotham Care Limited), Shruti Gupta (Sarvotham Care Limited), Sri Rama Krishna Kedarisetti (Sarvotham Care Limited), among others.